Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis (vol 326, pg 522, 2003)

被引：0
|
作者：
Chilcott, J.
机构：
来源：
BRITISH MEDICAL JOURNAL | 2007年 / 334卷 / 7595期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：685 / 685
页数：1
相关论文
共 50 条
  • [1] Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
    Chilcott, J
    McCabe, C
    Tappenden, P
    O'Hagan, A
    Cooper, NJ
    Abrams, K
    Claxton, K
    BRITISH MEDICAL JOURNAL, 2003, 326 (7388): : 522 - 525
  • [2] The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis
    Goodin, Douglas S.
    SEMINARS IN NEUROLOGY, 2013, 33 (01) : 13 - 25
  • [3] Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation`
    Melendez-Torres, G. J.
    Auguste, Peter
    Armoiry, Xavier
    Maheswaran, Hendramoorthy
    Court, Rachel
    Madan, Jason
    Kan, Alan
    Lin, Stephanie
    Counsell, Carl
    Patterson, Jacoby
    Rodrigues, Jeremy
    Ciccarelli, Olga
    Fraser, Hannah
    Clarke, Aileen
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (52) : I - +
  • [4] Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Izquierdo, Guillermo
    Duquette, Pierre
    Girard, Marc
    Grammond, Pierre
    Lugaresi, Alessandra
    Oreja-Guevara, Celia
    Bergamaschi, Roberto
    Hupperts, Raymond
    Grand'Maison, Francois
    Pucci, Eugenio
    Van Pesch, Vincent
    Boz, Cavit
    Iuliano, Gerardo
    Fernandez-Bolanos, Ricardo
    Flechter, Shlomo
    Spitaleri, Daniele
    Cristiano, Edgardo
    Verheul, Freek
    Lechner-Scott, Jeannette
    Amato, Maria Pia
    Antonio Cabrera-Gomez, Jose
    Saladino, Maria Laura
    Slee, Mark
    Moore, Fraser
    Gray, Orla
    Paine, Mark
    Barnett, Michael
    Havrdova, Eva
    Horakova, Dana
    Spelman, Timothy
    Trojano, Maria
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (09) : 1159 - 1171
  • [5] Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis (vol 72, pg 405, 2015)
    He, A.
    Spelman, T.
    Jokubaitis, V
    JAMA NEUROLOGY, 2015, 72 (08) : 950 - 950
  • [6] Beta interferon and glatiramer acetate: A novel approach to ensuring cost effectiveness
    Fletcher, G
    SCOTTISH MEDICAL JOURNAL, 2002, 47 (01) : 6 - 6
  • [7] Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis
    Ytterberg, C.
    Johansson, S.
    Anderson, M.
    Olsson, D.
    Link, H.
    Holmqvist, L. W.
    von Koch, L.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (02): : 96 - 99
  • [8] Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis (vol 72, pg 1411, 2015)
    Bourdette, D.
    Hartung, D.
    JAMA NEUROLOGY, 2015, 72 (12) : 1537 - 1537
  • [9] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
    Darba, J.
    Kaskens, L.
    Sanchez-de la Rosa, R.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [10] Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
    He, Anna
    Spelman, Tim
    Jokubaitis, Vilija
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Girard, Marc
    Pucci, Eugenio
    Iuliano, Gerardo
    Alroughani, Raed
    Oreja-Guevara, Celia
    Fernandez-Bolanos, Ricardo
    Grand'Maison, Francois
    Sola, Patrizia
    Spitaleri, Daniele
    Granella, Franco
    Terzi, Murat
    Lechner-Scott, Jeannette
    Van Pesch, Vincent
    Hupperts, Raymond
    Luis Sanchez-Menoyo, Jose
    Hodgkinson, Suzanne
    Rozsa, Csilla
    Verheul, Freek
    Butzkueven, Helmut
    Kalincik, Tomas
    JAMA NEUROLOGY, 2015, 72 (04) : 405 - 413
12345